Synergy Pharmaceuticals Named to NASDAQ Global Select Market

NEW YORK--()--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced listing of the company’s common stock has been transferred to the NASDAQ Global Select Market, the highest of the three market tiers at NASDAQ. Listing on the NASDAQ Global Select Market is reserved for companies that meet the highest quantitative and qualitative listing standards, reflecting their demonstrated commitments to leadership and good governance.

NASDAQ-listed companies are classified under three listing tiers: NASDAQ Global Select Market, NASDAQ Global Market, and NASDAQ Capital Market. Synergy common shares previously traded on the NASDAQ Capital Market and will continue to trade today on the NASDAQ Global Select Market under the ticker symbol SGYP.

About Synergy

Synergy Pharmaceuticals Inc. is a biotechnology company focused on the research and development of novel drugs for the treatment of gastrointestinal (GI) diseases and disorders. Synergy has discovered proprietary analogs of the human GI hormone, uroguanylin, the natural agonist for the intestinal guanylate cyclase-C (GC-C) receptor. Both Synergy’s lead GC-C agonist, plecanatide, and next-generation GC-C agonist, SP-333, mimic uroguanylin’s natural functions by binding to and activating the GC-C receptor in the GI tract to stimulate fluid and transit required for normal digestion. Plecanatide is in phase 3 clinical trials for chronic idiopathic constipation and a phase 2b study for irritable bowel syndrome with constipation. SP-333 is in phase 2 development for opioid-induced constipation and is also being explored for ulcerative colitis. For more information please visit www.synergypharma.com.

Contacts

Synergy Pharmaceuticals Inc.
Media
Gem Gokmen, Office: 212-584-7610
Mobile: 646-637-3208
ggokmen@synergypharma.com
or
Investors
Bernard Denoyer, Office: 212-297-0020
Mobile: 203-300-8147
bdenoyer@synergypharma.com

Release Summary

Synergy Pharmaceuticals Named to NASDAQ Global Select Market

Contacts

Synergy Pharmaceuticals Inc.
Media
Gem Gokmen, Office: 212-584-7610
Mobile: 646-637-3208
ggokmen@synergypharma.com
or
Investors
Bernard Denoyer, Office: 212-297-0020
Mobile: 203-300-8147
bdenoyer@synergypharma.com